

Therapeutic Lipidology

5th International Symposium, 2021

Joint Scientific Activity: Argentine Society of Cardiology, Argentine Federation of Cardiology, Argentine Society of Lipids, International Atherosclerosis Society. Atherosclerosis and Epidemiology Councils SAC and Lipids Committee of FAC.

Scientific & Society Coordinators: A Lozada, Raul Santos, Rodrigo Alonso, J Nogueira, A Lorenzatti, P Corral

Therapeutic Lipidology Meeting for Cardiologists, Endocrine and GPs: 26-Nov-2021

13:00hs: Conference: Evolocumab: 6 years in Clinical Practice. Kausik Ray (Coord Corral)

13:30 hs: Deciding the 2nd or 3rd Lipid Drug: Role of Calcium, Plaque and Costs.

(Coord Lorenzatti, Lozada)

13:30:hs. Case of a patient at Goal and with progression of ASCVD...Walter Masson

13:45 hs. UK's Inclisiran Population Health approach will influence Reimbursement Policy? Alonso

14:00 hs. Familial hypercholesterolemia: What tests to decide a 3rd or 4th drug? Corral

14.15 hs. Discussion

14:30 hs. Reimbursement for iPCSK9: how not to languish in the intent

(Coord Giunta Siniawski)

14:30 hs. A Successful Medical Summary for Reimbursement. Lozada

14:45 hs. Appeals and the Legal Process in Reimbursement. Comesaña.

15.00 hs. Discussion

15:15 hs: Guides: Are they to Aggressive or only based on Evidence

(Coord: Cuneo, Bonorino)

15:15 hs. ESC 2021 Guide: Will Colchicine Therapy be Prescribed ? Rafael Diaz/Lorenzatti

15:30 hs. Which Omega 3 in patients with ASCVD & TRL? J Nogueira

15:45 hs. LDL goals: will the rest of the world adopt the ESC goals? Ada Cuevas

16.00 hs. Discussion

16:15 hs: Coffee Break.

16.30 to 17.00: 3 Oral Posters of 10 min (FH, FCS & Lpa (Schraier, Nogueira, Gulayin)

17.00 hs: Residual Risk (RR) with Maximum Lipid Therapy: how to manage it?

(Coord, Carlos Ponte, P Corral)

17.00 hs. Two cases of patients: 1. with inflammation & 2. with moderate TG. J Nogueira

17:15 hs. Management of Residual Risk in patients with elevated TG. Henry Ginsberg

17:30 hs. Tx for patients with CRP / Inflammation causing RR. Lorenzatti

17:45 hs Discussion.

18:00 hs: Management of very high risk patients with very high Lipoprotein (a)

(Coord Nogueira, Giunta)

18:00 hs. Patient case with Extreme Lipoprotein (a) and Progression. D Siniawski

18:15 hs. RR caused by Lpa: is it enough with Statins or PCSK9-i? Rodrigo Alonso

18:45 hs. Discussion

Therapeutic Lipidology

5th International Symposium, 2021

Joint Scientific Activity: Argentine Society of Cardiology, Argentine Federation of Cardiology, Argentine Society of Lipids, International Atherosclerosis Society. Atherosclerosis and Epidemiology Councils SAC and Lipids Committee of FAC.

Scientific & Society Coordinators: A Lozada, Raul Santos, Rodrigo Alonso, J Nogueira, A Lorenzatti, P Corral

Meeting of the Lipidologists Club and Patients Associations: 27-Nov-2021

08.00 hs: Patient Associations in Latam: the Tasks for 2030.

(Coord Raul Santos, Lorenzatti)

08.00 hs. The Ibero-American HF Network: Proposals for LATAM. Rodrigo Alonso

08:15 hs. The successful founding of an NGO. Ruben Roldan

08:30 hs. Information Technology to capture patients with Rare Diseases. Georgina Sposetti

08:45 hs. Discussion.

09:00 hs. Proposal: Transition from a Registry to a Patient Association: Case of FCS. Nogueira

09:15 hs. Proposal: Transition from a Registry to a Patient Association: Lpa Case Maccalini/AL

09:30 hs. Proposal: Transition from a Registry to a Patient Association: Case of HF. Scherier

09:45 hs. Discussion

10:00 hs. Coffee

10:15 hs: Conference FCS Management- Renee Valero (Coord: Nogueira Cafferata)

10:45 hs: Management of statin intolerance(Coord Elikir, Masson)

10:45:hs Benpedoic acid: What is the Evidence so far. Raul Santos

11:00 hs: Use of PCSK9 in countries where statin intolerance indication is approved . Masson

11:15 hs. How to approve a Statin Intolerance Indication. Saidon (Anmat ,local FDA)

11.30 hs. Discussion

11 45.hs. Conference: PCSK9: What % of statin Intolerants will use it ? Ricardo Dent (Coord , Raul Santos; Giunta.)

12:15 hs. Coffee

12:15 hs Monitoring PCSK9 Inhibitor Therapy.(Coord: Lavallo. Masson)

12:15 hs. When to measure LDL post dose? Day 2, day 7 or day 14? Schreier

12:30 hs. Ultra low LDL: the Trials vs the Clinic. Rafael Diaz

12.45 hs. Discussion

Free Registration. Non-sponsored Multi-Society Hybrid Activity Buenos Aires. 11/27/2021